Xeris Free Cash Flow from 2010 to 2024
| XERS Stock | USD 3.45 0.27 8.49% |
Free Cash Flow | First Reported 2017-03-31 | Previous Quarter -10.7 M | Current Value -8.4 M | Quarterly Volatility 10.4 M |
Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 13.8 M or Interest Expense of 27.9 M, as well as many indicators such as Price To Sales Ratio of 1.88, Dividend Yield of 0.0 or Days Sales Outstanding of 154. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.
Xeris | Free Cash Flow |
Latest Xeris Pharmaceuticals' Free Cash Flow Growth Pattern
Below is the plot of the Free Cash Flow of Xeris Pharmaceuticals over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. Xeris Pharmaceuticals' Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xeris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Free Cash Flow | 10 Years Trend |
|
Free Cash Flow |
| Timeline |
Xeris Free Cash Flow Regression Statistics
| Arithmetic Mean | (45,564,353) | |
| Coefficient Of Variation | (77.52) | |
| Mean Deviation | 30,173,044 | |
| Median | (25,363,000) | |
| Standard Deviation | 35,323,735 | |
| Sample Variance | 1247.8T | |
| Range | 89.3M | |
| R-Value | (0.73) | |
| Mean Square Error | 621.3T | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | (5,791,454) | |
| Total Sum of Squares | 17468.7T |
Xeris Free Cash Flow History
Other Fundumenentals of Xeris Pharmaceuticals
Xeris Pharmaceuticals Free Cash Flow component correlations
About Xeris Pharmaceuticals Financial Statements
Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as Free Cash Flow, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Free Cash Flow | -49.3 M | -51.8 M | |
| Free Cash Flow Yield | (0.15) | (0.16) | |
| Free Cash Flow Per Share | (0.36) | (0.38) | |
| EV To Free Cash Flow | (9.85) | (9.35) | |
| Price To Free Cash Flows Ratio | (6.56) | (6.24) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.05 | 0.82 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.